Tonix Pharmaceuticals (TNXP) Receives Daily News Impact Rating of 0.24

Media stories about Tonix Pharmaceuticals (NASDAQ:TNXP) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Tonix Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.7519680319588 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment’s rankings:

A number of equities research analysts have weighed in on TNXP shares. ValuEngine upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Brookline Cap M restated a “buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, May 1st. Finally, Brookline Capital Management restated a “buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, May 1st. Seven analysts have rated the stock with a buy rating, Tonix Pharmaceuticals presently has an average rating of “Buy” and an average target price of $8.33.

Shares of Tonix Pharmaceuticals remained flat at $$3.10 during trading on Thursday, Marketbeat.com reports. 28,782 shares of the company were exchanged, compared to its average volume of 70,620. The firm has a market capitalization of $27.19 million, a PE ratio of -1.07 and a beta of 2.84. Tonix Pharmaceuticals has a 52-week low of $2.70 and a 52-week high of $4.99.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Monday, March 12th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10. sell-side analysts expect that Tonix Pharmaceuticals will post -2.68 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply